Treatment of Bacterial Vaginosis with Gule Dhawa

Clinical Study of Bacterial Vaginosis(Jarasime Iltehabe Mehbal)and its Management with Gule Dhawa(Woodfordia Fruticosa) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/060358

Enrollment

Registered

2023-11-30

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N768- Other specified inflammation of vagina and vulva

Interventions

Intervention1: Drug: Gule Dhawa (Woodfordia Fruticosa) Sufoof Dhawa and Roghane Neem: Mode Of Usage: Oral and Hummoul (Vaginal Suppository) Oral: Decoction Of Gule Dhawa 10gm Per Day (15ml) Maximum D

Eligibility

Inclusion criteria

Inclusion criteria: 1.Married patients between the age group 18 to 45 years 2.Complaining of vaginal discharge 3.Already diagnosed cases

Exclusion criteria

Exclusion criteria: 1.Patients presenting with blood-stained discharge 2.Pregnant lactating women 3.Trichomonas vaginitis candidiasis vaginitis 4.Patient with any organs pelvic pathology 5.Patient with systemic illness malignancy 6.Patients with AIDS, syphilis, Gonorrhoea 7.Patient with HTN, DM.

Design outcomes

Primary

Measure	Time frame
Vaginal swab culture Timepoint: Each Patient Outcome Depends on After 2 Cycles of Successful Oral Medicine ie 60days And Vaginal Suppository(HUMMOUL)Each Month 10 days	—

Secondary

Measure	Time frame
Changes in Amsels criteriaTimepoint: Each Patient Outcome Depends on After 2 Cycles of Successful Oral Medicine ie 60days And Vaginal Suppository(HUMMOUL)Each Month 10 days	—

Countries

India

Contacts

Public ContactDr Rayees Unnisa

Government Nizamia Tibbi College and General Hospital

drssntc@gmail.com9908624090

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026